Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
Portfolio Pulse from
Lifecore Biomedical has been chosen by Nirsum Labs to provide CDMO services for the clinical development of NRS-033, an innovative treatment for opioid use disorder. The services include tech transfer, process assessment, and method validation for a planned Phase 2 trial.
December 19, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lifecore Biomedical has been selected by Nirsum Labs to provide CDMO services for NRS-033, an innovative opioid use disorder treatment. This partnership involves tech transfer, process assessment, and method validation for a Phase 2 trial.
The partnership with Nirsum Labs positions Lifecore Biomedical as a key player in the development of a potentially impactful treatment for opioid use disorder. This could enhance Lifecore's reputation and lead to future business opportunities, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90